Published in Therap Adv Gastroenterol on March 01, 2010
Kupffer cells in the liver. Compr Physiol (2013) 1.12
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One (2011) 1.08
E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS One (2012) 0.99
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci (2013) 0.95
Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep (2012) 0.92
Lipotoxicity: effects of dietary saturated and transfatty acids. Mediators Inflamm (2013) 0.91
Cyanidin-3-O-β-glucoside regulates fatty acid metabolism via an AMP-activated protein kinase-dependent signaling pathway in human HepG2 cells. Lipids Health Dis (2012) 0.91
Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol (2013) 0.90
Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases. PPAR Res (2012) 0.83
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol (2015) 0.82
Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep (2012) 0.81
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
Herbal medicines for the treatment of nonalcoholic steatohepatitis: current scenario and future prospects. Evid Based Complement Alternat Med (2014) 0.80
Coacervate whey protein improves inflammatory milieu in mice fed with high-fat diet. Nutr Metab (Lond) (2014) 0.78
Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol (2011) 0.78
Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med (2015) 0.76
Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol (2015) 0.76
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol (2017) 0.75
A key problem and challenge for hepatology: Obesity-related metabolic liver diseases. World J Hepatol (2011) 0.75
Euterpe edulis Extract but Not Oil Enhances Antioxidant Defenses and Protects against Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet in Rats. Oxid Med Cell Longev (2016) 0.75
Non-alcoholic fatty liver and the gut microbiota. Mol Metab (2016) 0.75
Physiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP. Cell Metab (2016) 0.75
The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr (2014) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab (2004) 8.36
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med (2006) 5.54
Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India (2009) 5.45
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology (2001) 5.07
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ (2009) 4.44
Nonalcoholic fatty liver disease. Gastroenterology (2002) 4.15
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology (1990) 3.63
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology (2003) 3.51
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis (2006) 3.30
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 3.16
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr (2000) 2.88
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol (2005) 2.67
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol (2006) 2.49
Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol (2005) 2.46
Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol (2009) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol (2001) 2.11
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 2.11
Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition (2004) 2.09
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Non-alcoholic steatohepatitis: an overview. J Formos Med Assoc (2009) 2.08
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol (2009) 2.06
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology (2002) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol (2006) 2.02
Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol (2005) 1.93
Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology (2001) 1.92
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2005) 1.86
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Is NASH underdiagnosed among African Americans? Am J Gastroenterol (2002) 1.79
Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol (2004) 1.78
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther (2006) 1.74
Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther (2001) 1.73
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology (2009) 1.67
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2006) 1.67
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 1.62
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther (2004) 1.61
Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2004) 1.60
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther (2006) 1.58
Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol (1992) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology (2006) 1.56
Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol (2006) 1.56
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2008) 1.54
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Exercise and risk factors associated with metabolic syndrome in older adults. Am J Prev Med (2005) 1.51
Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49
VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology (2009) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol (1991) 1.45
Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol (2007) 1.43
Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology (1990) 1.40
Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr (2000) 1.39
Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int (2006) 1.37
Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol (2007) 1.36
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33
The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci (2007) 1.28
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 1.25
Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol (2009) 1.24
Dietary betaine promotes generation of hepatic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res (1993) 1.24
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol (2001) 1.24
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut (2010) 2.46
Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis (2007) 2.41
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol (2012) 2.11
Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci (2012) 2.11
Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology (2005) 2.07
Health-related quality of life in patients with chronic hepatitis B. Liver Int (2007) 1.90
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology (2011) 1.81
MELD fails to measure quality of life in liver transplant candidates. Liver Transpl (2005) 1.79
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med (2008) 1.72
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
A methodology for successfully producing global translations of patient reported outcome measures for use in multiple countries. Value Health (2009) 1.50
When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med (2010) 1.48
Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol (2007) 1.46
In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol (2012) 1.40
Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci (2014) 1.40
Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol (2002) 1.34
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.27
Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int (2007) 1.24
Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol (2010) 1.17
Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci (2007) 1.17
Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci (2004) 1.11
Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis (2008) 1.06
Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg (2005) 1.06
Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol (2005) 1.04
Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl (2008) 1.04
Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Obes Surg (2009) 1.04
Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg (2006) 1.03
The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res (2008) 1.02
Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis (2007) 1.01
Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol (2009) 0.99
Adipose tissue as an endocrine organ. Clin Liver Dis (2014) 0.98
Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics (2011) 0.98
Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis (2013) 0.96
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci (2013) 0.95
Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU. Chest (2004) 0.93
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med (2004) 0.93
Recent trends in inpatient mortality and resource utilization for patients with stroke in the United States: 2005-2009. J Stroke Cerebrovasc Dis (2013) 0.90
Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis (2009) 0.89
Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg (2008) 0.89
Association of chronic liver disease with depression: a population-based study. Psychosomatics (2013) 0.88
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2013) 0.88
Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med (2013) 0.88
Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg (2007) 0.87
Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg (2008) 0.87
Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. Expert Rev Gastroenterol Hepatol (2008) 0.87
Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion (2010) 0.87
Quality of life in cirrhosis. Curr Gastroenterol Rep (2013) 0.86
The impact of liver disease on health-related quality of life: a review of the literature. Curr Gastroenterol Rep (2002) 0.85
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol (2005) 0.85
Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. Obes Surg (2011) 0.85
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol (2014) 0.85
Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs (2010) 0.84
Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol (2012) 0.84
Validation of the chronic liver disease questionnaire in Serbian patients. World J Gastroenterol (2013) 0.83
The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int (2013) 0.83
Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn (2007) 0.83
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol (2005) 0.83
High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol (2005) 0.83
Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. J Gastroenterol Hepatol (2014) 0.83
The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology (2008) 0.82
Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med (2004) 0.81
Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics (2007) 0.81
Current treatment strategies for non-alcoholic fatty liver disease (NAFLD). Curr Drug Discov Technol (2007) 0.81
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care (2016) 0.81
African americans are less likely to have clearance of hepatitis C virus infection: the findings from recent U.S. population data. J Clin Gastroenterol (2012) 0.80
Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin Liver Dis (2009) 0.80
Hepatitis C virus infection and coronary artery disease risk: a systematic review of the literature. Dig Dis Sci (2014) 0.80
Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis (2005) 0.80
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol (2010) 0.80
Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study. Clin Drug Investig (2011) 0.79
Hepatic stellate cell and myofibroblast-like cell gene expression in the explanted cirrhotic livers of patients undergoing liver transplantation. Dig Dis Sci (2009) 0.79
Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int (2005) 0.79
Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history? Am J Gastroenterol (2003) 0.78
Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology (2002) 0.78
The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis (2007) 0.78
Measurement of health-related quality of life in patients with chronic liver disease. Liver Transpl (2006) 0.78
Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. Medicine (Baltimore) (2016) 0.78
Host genetic variants in obesity-related nonalcoholic fatty liver disease. Clin Liver Dis (2013) 0.77
Quality of life and liver transplantation in patients with polycystic liver disease. Liver Transpl (2006) 0.77
Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav (2012) 0.77
Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. Hepatology (2012) 0.77
Revolutionizing treatment outcomes in hepatitis C: managed care implications and considerations--diagnosis and management. Am J Manag Care (2015) 0.77
Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. Am J Gastroenterol (2010) 0.77
Inpatient economic and mortality assessment for liver transplantation: a nationwide study of the United States data from 2005 to 2009. Transplantation (2014) 0.77
Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2015) 0.76
Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil (2014) 0.76
Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD. Mediators Inflamm (2013) 0.76
Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. BMC Gastroenterol (2014) 0.76
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. J Clin Gastroenterol (2017) 0.75
Trends in Liver Transplantation in Hepatitis C Virus-Infected Persons, United States. Emerg Infect Dis (2016) 0.75
Long-term improvement in health-related quality of life after orthotopic liver transplantation. Liver Transpl (2008) 0.75